Related Experiment Video
Updated: Mar 11, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
DIFFERENTIAL PATHWAY DEPENDENCY DISCOVERY ASSOCIATED WITH DRUG RESPONSE ACROSS CANCER CELL LINES
Gil Speyer1, Divya Mahendra, Hai J Tran
1The Translational Genomics Research Institute, Phoenix, AZ 85004, U.S.A., gspeyer@tgen.org.
Abstract:
The effort to personalize treatment plans for cancer patients involves the identification of drug treatments that can effectively target the disease while minimizing the likelihood of adverse reactions. In this study, the gene-expression profile of 810 cancer cell lines and their response data to 368 small molecules from the Cancer Therapeutics Research Portal (CTRP) are analyzed to identify pathways with significant rewiring between genes, or differential gene dependency, between sensitive and non-sensitive cell lines. Identified pathways and their corresponding differential dependency networks are further analyzed to discover essentiality and specificity mediators of cell line response to drugs/compounds. For analysis we use the previously published method EDDY (Evaluation of Differential DependencY). EDDY first constructs likelihood distributions of gene-dependency networks, aided by known genegene interaction, for two given conditions, for example, sensitive cell lines vs. non-sensitive cell lines. These sets of networks yield a divergence value between two distributions of network likelihoods that can be assessed for significance using permutation tests. Resulting differential dependency networks are then further analyzed to identify genes, termed mediators, which may play important roles in biological signaling in certain cell lines that are sensitive or non-sensitive to the drugs. Establishing statistical correspondence between compounds and mediators can improve understanding of known gene dependencies associated with drug response while also discovering new dependencies. Millions of compute hours resulted in thousands of these statistical discoveries. EDDY identified 8,811 statistically significant pathways leading to 26,822 compound-pathway-mediator triplets. By incorporating STITCH and STRING databases, we could construct evidence networks for 14,415 compound-pathway-mediator triplets for support. The results of this analysis are presented in a searchable website to aid researchers in studying potential molecular mechanisms underlying cells' drug response as well as in designing experiments for the purpose of personalized treatment regimens.
Insights
This study analyzes cancer cell line gene expression and drug response data to find key gene pathways driving drug sensitivity. The findings identify potential drug targets and mediators for personalized cancer treatments.
Area of Science:
- Genomics
- Computational Biology
- Pharmacology
Background:
- Personalized cancer treatment requires identifying effective drugs with minimal adverse reactions.
- Understanding gene-drug interactions is crucial for tailoring therapies.
Purpose of the Study:
- To identify gene pathways with differential dependency in cancer cell lines sensitive or non-sensitive to drugs.
- To discover mediators of drug response for personalized medicine.
Main Methods:
- Analysis of gene-expression profiles from 810 cancer cell lines and response data to 368 small molecules from the Cancer Therapeutics Research Portal (CTRP).
- Utilized the Evaluation of Differential DependencY (EDDY) method to construct gene-dependency networks and assess pathway rewiring.
- Permutation tests were used to determine the statistical significance of differential gene dependency.
Main Results:
- Identified 8,811 statistically significant pathways and 26,822 compound-pathway-mediator triplets.
- Constructed evidence networks for 14,415 triplets using STITCH and STRING databases.
- Discovered potential mediators influencing cell line sensitivity or resistance to specific drugs.
Conclusions:
- The study provides a valuable resource for understanding molecular mechanisms of drug response in cancer.
- Findings can aid researchers in designing personalized treatment regimens and discovering novel drug dependencies.
More Related Videos
10:09Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Treatment Resistant Cancers
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Drug Discovery: Overview